Phase-I study of Innacell γδTM, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

Phase-I study of Innacell γδTM, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

Saved in:
Bibliographic Details
Published in:Cancer immunology and immunotherapy Vol. 57; no. 11; pp. 1599 - 1609
Main Authors: BENNOUNA, Jaafar, BOMPAS, Emmanuelle, LAFAYE-DE MICHEAUX, Sylvie, TIOLLIER, Jerome, NEGRIER, Sylvie, NEIDHARDT, Eve Marie, ROLLAND, Frederic, PHILIP, Irène, GALEA, Celine, SALOT, Samuel, SAIAGH, Soraya, AUDRAIN, Marie, RIMBERT, Marie
Format: Journal Article
Language:English
Published: Berlin Springer 2008
Subjects:
Antineoplastic agents
Biological and medical sciences
Immunotherapy
Kidneys
Medical sciences
Nephrology. Urinary tract diseases
Pharmacology. Drug treatments
Tumors of the urinary system
Carcinoma
Cell therapy
Interleukin-2
Toxicity
Clinical efficacy
Metastasis
Interleukin 2
Immunotherapy
T-Lymphocyte
Safety and tolerability
Grawitz tumor
Advanced stage
Safety
Kidney disease
Human
Metastatic renal cell carcinoma
Drug combination
Urinary system disease
Treatment efficiency
Cytokine
Autologous system
Malignant tumor
γ9δ2 T lymphocytes
Treatment
Kidney cancer
Phase I trial
Cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0340-7004
1432-0851